ORBIMED ADVISORS LLC 13D and 13G filings for Theravance Biopharma, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-02-14 5:07 pm Sale | 2022-12-31 | 13G | Theravance Biopharma, Inc. TBPH | ORBIMED ADVISORS LLC | 0 0.000% | -5,456,780 (Position Closed) | Filing |
| 2022-02-11 4:49 pm Sale | 2021-12-31 | 13G | Theravance Biopharma, Inc. TBPH | ORBIMED ADVISORS LLC | 5,456,780 7.400% | -87,432 (-1.58%) | Filing |
| 2021-02-12 5:10 pm Purchase | 2020-12-31 | 13G | Theravance Biopharma, Inc. TBPH | ORBIMED ADVISORS LLC | 5,544,212 8.670% | 5,544,212 (New Position) | Filing |